Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?

Jared H. Gans, Jeffrey Lipman, Yosef S. Golowa, Milan Kinkhabwala, Andreas Kaubisch

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Hepatocellular cancer (HCC) is most common primary liver malignancy in adults. Treatment for HCC is a multispecialty undertaking, with surgical, locoregional, and systemic options available. Choice of treatment depends upon patient and disease factors. Surgical therapy, including resection and transplantation, is the primary curative treatment and is best suited to patients with early disease. More advanced disease may be amenable to locoregional therapies to “bridge” to transplantation, downstage disease, or as destination therapy for unresectable cases. These include percutaneous ablation, transarterial therapy, external radiation, and radioembolization with yttrium-90 conjugated beads. Patients with more advanced disease may benefit most from systemic chemotherapeutic or small molecule inhibitor options available, many of which have only been recently FDA approved. Immunotherapy is the newest component of HCC treatment. The Y-90 consultant should be familiar with all modalities of HCC treatment and the interplay between them.

Original languageEnglish (US)
JournalSeminars in nuclear medicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Liver Neoplasms
Microspheres
Therapeutics
Transplantation
Yttrium
Consultants
Immunotherapy
Radiotherapy
Liver
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{02e918b1bd1240d484e2d0438e722c8f,
title = "Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?",
abstract = "Hepatocellular cancer (HCC) is most common primary liver malignancy in adults. Treatment for HCC is a multispecialty undertaking, with surgical, locoregional, and systemic options available. Choice of treatment depends upon patient and disease factors. Surgical therapy, including resection and transplantation, is the primary curative treatment and is best suited to patients with early disease. More advanced disease may be amenable to locoregional therapies to “bridge” to transplantation, downstage disease, or as destination therapy for unresectable cases. These include percutaneous ablation, transarterial therapy, external radiation, and radioembolization with yttrium-90 conjugated beads. Patients with more advanced disease may benefit most from systemic chemotherapeutic or small molecule inhibitor options available, many of which have only been recently FDA approved. Immunotherapy is the newest component of HCC treatment. The Y-90 consultant should be familiar with all modalities of HCC treatment and the interplay between them.",
author = "Gans, {Jared H.} and Jeffrey Lipman and Golowa, {Yosef S.} and Milan Kinkhabwala and Andreas Kaubisch",
year = "2019",
month = "1",
day = "1",
doi = "10.1053/j.semnuclmed.2019.01.001",
language = "English (US)",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Hepatic Cancers Overview

T2 - Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?

AU - Gans, Jared H.

AU - Lipman, Jeffrey

AU - Golowa, Yosef S.

AU - Kinkhabwala, Milan

AU - Kaubisch, Andreas

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hepatocellular cancer (HCC) is most common primary liver malignancy in adults. Treatment for HCC is a multispecialty undertaking, with surgical, locoregional, and systemic options available. Choice of treatment depends upon patient and disease factors. Surgical therapy, including resection and transplantation, is the primary curative treatment and is best suited to patients with early disease. More advanced disease may be amenable to locoregional therapies to “bridge” to transplantation, downstage disease, or as destination therapy for unresectable cases. These include percutaneous ablation, transarterial therapy, external radiation, and radioembolization with yttrium-90 conjugated beads. Patients with more advanced disease may benefit most from systemic chemotherapeutic or small molecule inhibitor options available, many of which have only been recently FDA approved. Immunotherapy is the newest component of HCC treatment. The Y-90 consultant should be familiar with all modalities of HCC treatment and the interplay between them.

AB - Hepatocellular cancer (HCC) is most common primary liver malignancy in adults. Treatment for HCC is a multispecialty undertaking, with surgical, locoregional, and systemic options available. Choice of treatment depends upon patient and disease factors. Surgical therapy, including resection and transplantation, is the primary curative treatment and is best suited to patients with early disease. More advanced disease may be amenable to locoregional therapies to “bridge” to transplantation, downstage disease, or as destination therapy for unresectable cases. These include percutaneous ablation, transarterial therapy, external radiation, and radioembolization with yttrium-90 conjugated beads. Patients with more advanced disease may benefit most from systemic chemotherapeutic or small molecule inhibitor options available, many of which have only been recently FDA approved. Immunotherapy is the newest component of HCC treatment. The Y-90 consultant should be familiar with all modalities of HCC treatment and the interplay between them.

UR - http://www.scopus.com/inward/record.url?scp=85061669119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061669119&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2019.01.001

DO - 10.1053/j.semnuclmed.2019.01.001

M3 - Review article

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

ER -